Background GC constitutes the second most commonly reportable disease in the United States with over 320,000 cases annually. With the emergence of drug-resistant GC in the past 40 years, treatment options have become very limited. Hence, the U.S. Department of Defense has launched a GC resistance surveillance network in 8 countries; preliminary results are reported from the United States, Djibouti, Ghana, Kenya, and Peru.

Methods Patients with urethritis, cervicitis or vaginitis symptoms were recruited at participating clinics serving military personnel and beneficiaries, civilians, and at-risk groups of men who have sex with men and female commercial sex workers. Urethral swabs were collected from men; urethral or vaginal swabs from women; diagnosis was done using culture identification, nucleic acid amplification testing, and real-time PCR. Antimicrobial susceptibility testing (AST) was conducted on GC positive isolates using real-time PCR, disc diffusion, and E-test strip methods.

Results Overall, 108 (6%) of 1,694 enrolled subjects tested positive for GC. Prevalence was found to be highest in Kenya where 35 (38%) of 86 patients were positive and was lowest in Peru where only 30 (2%) of 1,296 patients were positive. AST results were available on 66 GC positives; resistance to at least three antibiotics was observed across all overseas sites. Greatest variability in resistance was noted in Djibouti as follows: penicillin (100%), tetracycline (88%), ciprofloxacin (38%), levofloxacin (17%), cefepime (13%), and ceftriaxone (13%). High-level resistance (100%) was also noted in Ghana to ciprofloxacin, penicillin, and tetracycline.

Conclusion These findings provide evidence of emerging drug-resistant GC in several regions of the world; the resistance found against third-generation cephalosporin in Djibouti is especially noteworthy. With continuing global vigilance, GC drug resistance information will provide an important basis for the development of effective control measures, particularly among deployable forces and at-risk populations in geographical regions of military relevance.

Background The incidence of gonococcal infections in Estonia peaked in 1993 with an infection rate of 233 cases/100,000 population and declined to 16.2 cases/100,000 population in 2012. The greatest part of clinical laboratories desists from N. gonorrhoeae cultivation. 100% of Neisseria gonorrhoeae diagnosis in Estonia is made by DNA detection techniques. Different tests are in use: Rapid DNA probe GEN-PROBE PACE (Gen-Probe Incorporated San Diego, USA), PCR with in house made primers other commercially available STI tests.

Aims to improve laboratory diagnosis of gonorrhoea and monitoring of antimicrobial susceptibilities of N. gonorrhoeae to investigate treatment failure and to evaluate the efficacy of currently recommended therapies.

Methods In 2007, Estonian IJUSTI branch has elaborated National Guidelines for the STI management (on the base of the European STD Guidelines and Eastern European Network for Sexual and Reproductive Health) with it’s second revision in 2011. For N. gonorrhoeae diagnosis was recommended to start with molecular test and then if positive to continue with cultural method, using disc diffusion method and E-tests for AMR. WHO reference panel N.gonorrhoeae was obtained from reference laboratory in Örebro, Sweden.

Results Totally 24 isolates obtained. Gonococci (14) were collected from urethral swabs of men, 8 strains were isolated from female cervical swabs, gender was unknown for 2 cases (anonymous). AMR detected in 4 isolates; 2 were strains isolated after treatment failure: one - resistant to Pen, Tetra, Cipro and susceptible to Ceftriaxone; second - resistant to Pen, Tetra, Cipro and had decreased susceptibility (resistance) to Ceftriaxone (MIC 0.25mg/L). In addition in 2 isolates MICs to Ceftriaxone were 0.38mg/L and 0.50 mg/L. AMR were detected to penicillin (12.5%), to ciprofloxacin (8.4%) and to tetracycline (8.4%).

Conclusion Gonorrhoea may become untreatable under certain circumstances and surveillance of N. gonorrhoeae AMR is crucial in Estonia.
Background

While there is evidence that gonococcal antimicrobial resistance (GC AMR) is increasing in parts of Canada, a national, standardised surveillance system does not currently exist to confirm these suspicions or identify the risks associated with acquiring a resistant GC infection.

Methods

Currently, laboratory-based surveillance of GC AMR is standard practice for all positive gonorrhoea isolates tested by culture in Canada. Nine out of 13 provinces/territories employ culture for a proportion of the total gonorrhoea tests done in their jurisdictions (typically conducted by local/regional laboratories). Variation in methods at the provincial/territorial (P/T) level and limited epidemiologic data on resistant GC isolates limits national level surveillance.

To address gaps in current systems, a national protocol for GC AMR has been developed and approved by the Health Canada-Public Health Agency of Canada Research Ethics Board, and recruitment of P/T health authorities is in progress. Due to P/T variations in public health legislation and health care practises, recruitment has necessitated innovative solutions to address the individual needs of jurisdictions while ensuring the coherence and comparability of the resulting data.

Results

In 2011, the proportion of GC isolates resistant to azithromycin, penicillin, erythromycin, ciprofloxacin and tetracycline was 0.4%, 22.2%, 26.6%, 29.3%, and 29.4%, respectively. Enhanced surveillance in two jurisdictions is expected to commence in 2013. Although slightly different mechanisms are being used to address provincial needs, efforts are being made to ensure that resulting data are consistent and adhere to the national protocol.

Conclusion

In Canada, surveillance of GC AMR is challenged by variations in practice and legislation at the P/T level and competing priorities at all levels of government. Through collaboration with public health partners, progress is being made in obtaining data for analysis of national-level trends to assess risk factors associated with GC AMR and guide treatment recommendations.

Methods

Descriptive retrospective study of NG strains isolated during 2011 and 2012. The susceptibility to cefixime, ceftriaxone, gentamicin and ciprofloxacin was performed using agar dilution (AD) and disc diffusion (DD) methods according to the CLSI guidelines.

Results

A total of 275 NG strains were isolated: 145 urethral (52%), 47 rectal (17%), 44 pharyngeal (16%), 28 endocervical (10%), vaginal and 13 (5%), belonging to 225 patients (174 men (77.3%), 51 (22.7%) women). The average age was 33.32 years (15–58 years). About 80% of the samples (221) were from STD Clinics Infectious Service. 151 patients (67.1%) were symptomatic at the moment of diagnosis, 32 cases (14.2%) were detected during screening and 42 cases (18.7%) during contact tracing. Urethritis was the most common clinical manifestation in men and accounted 71%, 3% of the cases.

All strains were susceptible to TGC by both methods. Ciprofloxacin showed 59.3% resistant strains by AD with low minor discordances between the two methods in 22 strains. 74.5% of the strains showed a MIC of $\geq 8\mu$g/ml to gentamicin (range: 2 – 16$\mu$g/ml), and inhibition zone in the DD method between 16 and 38 mm.

Conclusions

During the study period we found no resistant strains to TGC, but it was recorded a high rate of resistance to ciprofloxacin. The susceptibility profile of gentamicin is similar to those published but further research is needed to establish clinical breakpoints and doing a treatment recommendation.